1. Accelerating the development of innovative cellular therapy products for the treatment of cancer.
- Author
-
Stewart, Mark D., Keane, Anne, Butterfield, Lisa H., Levine, Bruce L., Thompson, Bruce, Xu, Yuan, Ramsborg, Chris, Lee, Ann, Kalos, Michael, Koerner, Chin, Moore, Timothy, Markovic, Ingrid, Lasiter, Laura, Ibrahim, Ramy, Bluestone, Jeffrey, Sigal, Ellen, and Allen, Jeff
- Subjects
- *
CELLULAR therapy , *CANCER treatment , *T cell receptors , *CHIMERIC antigen receptors , *NEW product development , *MANUFACTURED products - Abstract
The field of cell therapy is rapidly emerging as a priority area for oncology research and drug development. Currently, two chimeric antigen receptor T-cell therapies are approved by the US Food and Drug Administration and other agencies worldwide for two types of hematologic cancers. To facilitate the development of these therapies for patients with life-threatening cancers with limited or no therapeutic options, science- and risk-based approaches will be critical to mitigating and balancing any potential risk associated with either early clinical research or more flexible manufacturing paradigms. Friends of Cancer Research and the Parker Institute for Cancer Immunotherapy convened an expert group of stakeholders to develop specific strategies and proposals for regulatory opportunities to accelerate the development of cell therapies as promising new therapeutics. This meeting took place in Washington, DC on May 17, 2019. As academia and industry expand research efforts and cellular product development pipelines, this report summarizes opportunities to accelerate entry into the clinic for exploratory studies and optimization of cell products through manufacturing improvements for these promising new therapies. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF